ArticleCureus2026
Brewing an Interaction: Non-commercial Green Tea-Associated Supratherapeutic Tacrolimus Levels Presenting With Gastrointestinal Symptoms.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index and can have significant interactions with foods and herbs that affect CYP3A4 and P-gp metabolism. We report a case of gastrointestinal symptoms associated with supratherapeutic tacrolimus levels due to heavy consumption of non-commercial green tea with orange extract in a 44-year-old woman with Primary Sclerosing Cholangitis status post liver transplant and refractory Crohn's disease. She presented with worsening abdominal pain, nausea, and bloating while on a stable tacrolimus dose with previously therapeutic trough levels. Evaluation showed a supratherapeutic tacrolimus trough of 18.3 ng/mL without evidence of infection, hepatic dysfunction, or acute inflammatory bowel disease flare. Endoscopic findings were unchanged from prior examinations. Tacrolimus was held and green tea discontinued, leading to rapid normalization of tacrolimus levels and complete symptom resolution within 24 hours without corticosteroid escalation. Tacrolimus was later resumed at the prior dose with stable therapeutic levels during follow-up. This case highlights the potential for non-commercial herbal preparations, including green tea products, to alter tacrolimus metabolism and cause clinically significant toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.